Latest news and press releases about Biomea Fusion, Inc. (BMEA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; an...
Price
| Price | $1.74 |
| Market Cap | $126M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 12.54 |
| EV / EBITDA | -3.30 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -171.19% |
| Return on Invested Capital | -212.95% |
| Return on Assets | -88.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · CAMP · CBUS · GUTS · IMUX · PMVP
Explore sector: Healthcare · Biotechnology
More sections of BMEA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks